Immunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS Trial

Immunic Inc. (NASDAQ:IMUX) is one of the best penny stocks under $1 to buy now. On June 24, Immunic reported positive long-term open-label extension/OLE data from its Phase 2 EMPhASIS trial. The trial evaluated vidofludimus calcium (IMU-838), which is an orally available nuclear receptor-related 1 (Nurr1) activator, in patients with relapsing-remitting multiple sclerosis/RRMS.

The cumulative data from the EMPhASIS OLE period, which shows ~952 treatment years, further support the favorable safety and tolerability profile of vidofludimus calcium, showing low discontinuation rates and minimal treatment-emergent and serious adverse events. Importantly, no new safety signals have emerged during treatment durations extending up to 5.5 years. The Phase 2 EMPhASIS trial was an international, multicenter, double-blind, placebo-controlled, randomized, parallel-group study that initially randomized 268 RRMS patients.

A closeup of pills in a pharmacy, representing the high quality medications of the company.

Vidofludimus calcium (IMU-838) is an orally administered investigational small molecule drug in late-stage clinical trials for multiple sclerosis. Its unique dual mode of action combines neuroprotective, anti-inflammatory, and anti-viral effects. It acts as a selective immune modulator by activating the neuroprotective transcription factor Nurr1, which provides direct and indirect neuroprotective benefits.

Immunic Inc. (NASDAQ:IMUX) is a biotechnology company that develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the US and Germany.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.